2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19202
    rac-Olodanrigan 152362-51-1 98%
    rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT2 receptor antagonist with IC50s of 75.2 nM and 2918 nM for AT2R and AT1R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve.
    rac-Olodanrigan
  • HY-19206
    R-84760 157824-23-2 98%
    R-84760 is a selective κ-opioid receptor agonist. R-84760 has antinociceptive effect.
    R-84760
  • HY-19250
    U-101017 170568-47-5 98%
    U-101017 is a partial agonist of benzodiazepine receptor and GABAA receptor, with anxiolytic effects. 
    U-101017
  • HY-19465
    Dasolampanel 503294-13-1 98%
    Dasolampanel is a kainate receptor antagonist that helps regulate the excitability of the nervous system by blocking kainate receptors and reducing glutamate-mediated excitatory transmission. Dasolampanel can be used in the study of diseases such as overexcitement and sleep disorders.
    Dasolampanel
  • HY-19467
    SCH 486757 524019-25-8 98%
    SCH 486757 is an orally effective pain peptide receptor (NOP) agonist. SCH 486757 can be used for the study of cough.
    SCH 486757
  • HY-19483
    ABT-670 630119-43-6 98%
    ABT-670 is a selective, oral bioavailable agonist of dopamine D4 receptor, with EC50 of 89 nM, 160 nM, and 93 nM for human D4, ferret D4, and rat D4, respectively.
    ABT-670
  • HY-19646
    Zoliprofen 56355-17-0 98%
    Zoliprofen (480156-S), a new non-steroidal anti-inflammatory agent, has potent pain suppressing effect. Zoliprofen has strong antagonistic action against bradykinin, markedly inhibiting all bradykinin-induced edema and pain reactions. Zoliprofen weakly inhibits Arachidonic acid (HY-109590)-induced edema and pain reactions but also inhibits PGE2 synthesis of bovine vesicular gland microsomes.
    Zoliprofen
  • HY-19658
    Serazapine 115313-22-9 98%
    Serazapine (CPDD-0035) is a selective 5-HT2 antagonist. Serazapine is an anxiolytic.
    Serazapine
  • HY-19670
    Befetupitant 290296-68-3 98%
    Befetupitant is a high-affinity, nonpeptide, competitive tachykinin 1 receptor (NK1R) antagonist.
    Befetupitant
  • HY-19682
    Enciprazine 68576-86-3 98%
    Enciprazine is a potent agonist 5-HT1A receptor. Enciprazine shows anxiolytic activity, and can be used in the research of anxiety disorders, and depression.
    Enciprazine
  • HY-19684
    Pancopride 121650-80-4 98%
    Pancopride is a new potent and selective 5-HT3 receptor antagonist.
    Pancopride
  • HY-19692
    Itasetron 123258-84-4 98%
    Itasetron (DA 6215) is a selective 5-HT3 receptor antagonist. Itasetron improves spatial learning and memory abilities in the aged rat. Itasetron has potent antiemetic properties. Itasetron is used for age-related memory degeneration in rodents.
    Itasetron
  • HY-19899
    APD-916 1021169-11-8 98%
    APD-916 is an H3 receptor antagonist. APD-916 shows good pharmacokinetic properties, and oral administration of APD-916 has been shown to enhance wakefulness in various animal models.
    APD-916
  • HY-19907
    Liafensine 1198790-53-2 98%
    Liafensine (BMS-820836) is a triple monoamine reuptake inhibitor (TRI), that inhibits dopamine transporter, serotonin transporter and norepinephrine transporter, with IC50s of 5.67, 1.08 and 7.99 nM, respectively. Liafensine exhibits antidepressant activity.
    Liafensine
  • HY-19917
    JNJ-39220675 959740-39-7 98%
    JNJ-39220675 is a selective and brain-penetrating histamine H3 receptor antagonist with activity in regulating alcohol stimulation and reward. JNJ-39220675 is effective in reducing alcohol intake and preference in alcohol-preferring rats. JNJ-39220675 does not affect the ataxic effects of alcohol, the rate of alcohol elimination, or alcohol-induced nucleocapsid dopamine release.
    JNJ-39220675
  • HY-21098
    PD-168077 190383-31-4 98%
    PD-168077 is a selective dopamine D4 receptor agonist, with a Ki of 9 nM.
    PD-168077
  • HY-28259
    2-Bromo-3',4'-(methylenedioxy)propiophenone 52190-28-0 98%
    2-Bromo-3',4'-(methylenedioxy)propiophenone is a precursor in the synthesis of cathinones.
    2-Bromo-3',4'-(methylenedioxy)propiophenone
  • HY-34713
    N-Methylphenethylamine hydrochloride 4104-43-2 98%
    N-Methylphenethylamine (NMPEA) hydrochloride is a potent TAAR1 agonist. N-Methylphenethylamine hydrochloride also is a trace amine neuromodulator.
    N-Methylphenethylamine hydrochloride
  • HY-42225
    Methyl 7α-hydroxy-3-ketocholanoate 14773-00-3 98%
    Methyl 7α-hydroxy-3-ketocholanoate is a bile acid compound that can be used in neurological disease research.
    Methyl 7α-hydroxy-3-ketocholanoate
  • HY-43421
    Solifenacin N-oxide 180272-28-0 98%
    Solifenacin N-oxide (Solifenacin N1-oxide) is an inactive metabolite of the muscarinic receptor antagonist Solifenacin (HY-A0034).
    Solifenacin N-oxide
Cat. No. Product Name / Synonyms Application Reactivity